Is Ozempic Safe with Ketamine Therapy?

If you're on Ozempic, Wegovy, Mounjaro, Zepbound, or another GLP-1 agonist and considering at-home ketamine therapy, the combination is safe and we manage it with small session-day adjustments rather than any change to your underlying medication. The two medications work on entirely different systems, and there's no documented pharmacologic interaction to worry about. What we do manage is the session-day picture: GLP-1s slow gastric emptying and can cause nausea, ketamine can independently cause nausea, and stacking those two on the same day without preparation is the avoidable problem. The fix is straightforward.

Why this question comes up so often now

GLP-1 receptor agonists have moved from a relatively niche diabetes medication class to one of the most prescribed drug families in the country. Patients arrive at Tovani on Ozempic (semaglutide) prescribed for type 2 diabetes, on Wegovy (the same molecule branded for weight loss), on Mounjaro and Zepbound (tirzepatide, a GLP-1/GIP dual agonist), on Saxenda or Victoza (liraglutide), or on Rybelsus (oral semaglutide). The class is also being studied for cardiovascular protection, sleep apnea, and other indications, so the patient population is expanding fast. The question of how GLP-1s interact with at-home ketamine is now one of the more common questions we field.

The honest answer is that the pharmacology is reassuring and the operational considerations are manageable, but the question deserves a real treatment because patients have legitimate concerns: GLP-1s are new enough that long-term data is still emerging, the class has had its own safety conversations (gastric emptying, ileus risk in anesthesia, mood effects), and the interaction with a psychoactive medication isn't intuitively obvious.

The pharmacology, simply

GLP-1 receptor agonists work by mimicking the natural incretin hormone GLP-1, which is released by the gut in response to food intake. They bind GLP-1 receptors on pancreatic beta cells (enhancing insulin release in response to glucose), on the brain's hypothalamus (reducing appetite), and on the gastrointestinal tract (slowing gastric emptying). Tirzepatide adds GIP receptor agonism on top of the GLP-1 mechanism, which is why it produces more robust weight loss and glucose control.

Ketamine works on glutamate. Its primary action is NMDA receptor antagonism, triggering downstream effects including AMPA receptor activation and BDNF release. There is no shared receptor system between GLP-1 agonists and ketamine, no shared metabolic pathway, no documented pharmacokinetic interaction (GLP-1s do not meaningfully induce or inhibit the CYP enzymes that handle ketamine), and no documented pharmacodynamic interaction at the level of the drugs themselves.

The major published reviews on ketamine drug interactions have not identified GLP-1 agonists as a concern. The reason isn't that researchers haven't looked carefully; it's that the two drug classes don't share any of the mechanisms that produce meaningful interactions elsewhere in psychiatry (serotonergic stacking, CNS depression stacking, sympathomimetic stacking, or hepatic enzyme competition). The combination is pharmacologically clean.

What we do manage: the session-day picture

The clinical adjustment we make for GLP-1 patients is operational, not pharmacologic. Two things drive it.

Delayed gastric emptying. GLP-1 agonists slow gastric emptying significantly, which is part of how they reduce appetite and improve glucose control. Food that you would normally clear in 90 minutes can take 4-6 hours or longer. For a ketamine session, residual food in the stomach increases the chance of session-time nausea or vomiting, and the standard 2-3 hour pre-session fast that works for non-GLP-1 patients isn't enough when gastric emptying is slowed.

Independent nausea pathways. GLP-1 agonists cause nausea in many patients through their gastric and central effects. Ketamine independently causes nausea through its own central mechanisms during the acute session. The two pathways are separate, but the patient-level experience compounds: a patient who tolerates either one alone may have more session-time nausea when both are on board, especially with food in the stomach.

The Tovani session-day protocol for GLP-1 patients addresses both:

Extend the fast. No solid food for 4-6 hours minimum before the session. Avoid greasy or protein-heavy meals on the day of the session even within the allowed window before the fast begins. Clear fluids (water, clear broth, herbal tea without milk) up to about 2 hours before are fine and help with hydration.

Pre-medicate with ondansetron if you've had nausea on your GLP-1 in the past. Ondansetron 4 mg taken 30-60 minutes before the session substantially reduces the probability of intra-session nausea. We can write the prescription as part of intake. For patients who haven't had GLP-1 nausea, pre-medication is optional but reasonable as a precaution for the first session.

Hydrate aggressively the day before. Dehydration amplifies nausea and is easy to fix preventively. We recommend an extra 16-24 ounces of water the day before each session, beyond your normal intake.

Separate injection day from ketamine session day when scheduling allows. GLP-1 injection day is usually the day with the most GI side effects in the weekly cycle. Putting ketamine session on a different day of the week from injection day gives the best tolerability picture. For most patients on weekly Ozempic or Wegovy, this is easy to arrange: inject on Saturday, schedule ketamine sessions Tuesday or Wednesday.

These four adjustments together cost almost nothing in terms of treatment complexity and substantially improve session-day comfort.

The GLP-1 + mood question, separately

Patients sometimes ask whether GLP-1s themselves can affect mood, and the honest answer is that the field doesn't fully know yet. The European Medicines Agency conducted a safety review of GLP-1 agonists in 2023-2024 after reports of suicidal thoughts and self-harm in some patients on the class; the review did not establish a causal link but did note that monitoring for mood changes is appropriate. A 2024 case report (Rajaram Manoharan et al., Innovations in Clinical Neuroscience, PMID 38938530) documented worsened depression in a patient starting Ozempic, and the authors noted that "their impact on mood and other psychiatric manifestations remains uncertain because of inconsistent data." Larger cohort studies have produced inconsistent signals, with some suggesting elevated psychiatric diagnoses in GLP-1 users and others showing protective effects.

This is a meaningfully separate question from "is the combination safe with ketamine." For ketamine therapy purposes, the relevance is:

If you've experienced new or worsening depression or mood instability since starting your GLP-1, mention it at intake. Sometimes a patient's worsening depression is the reason they're considering ketamine therapy in the first place, and it's useful to know whether the GLP-1 is a contributing factor we should think about. Talking with your prescribing physician about whether to continue, adjust, or change the GLP-1 may be part of the conversation.

If your mood has been stable on the GLP-1, this question doesn't change anything for your intake. We treat you the same as any patient on any other chronic medication: continue the GLP-1, use the session-day adjustments above, proceed with standard ketamine onboarding.

Specific GLP-1 agents this page covers

The session-day protocol applies to all GLP-1 receptor agonists and GLP-1/GIP dual agonists:

Semaglutide is marketed as Ozempic (subcutaneous, weekly, for type 2 diabetes), Wegovy (subcutaneous, weekly, higher doses for weight loss), and Rybelsus (oral, daily, for type 2 diabetes).

Tirzepatide is marketed as Mounjaro (subcutaneous, weekly, for type 2 diabetes) and Zepbound (same molecule, weight loss indication). Tirzepatide is a dual GLP-1/GIP agonist; the same session-day rules apply because the GLP-1 component drives the gastric emptying and nausea concerns.

Liraglutide is marketed as Victoza (daily injection, type 2 diabetes) and Saxenda (daily injection, weight loss). Older than the weekly agents; same class effects.

Dulaglutide (Trulicity), exenatide (Byetta, Bydureon) are older or less-common GLP-1 agonists where the same considerations apply.

For all of these, the session-day adjustment is the same: extend the fast, consider ondansetron pre-medication, hydrate aggressively, separate injection day from session day when possible.

What we do at intake

When a patient is on a GLP-1, our intake process includes:

The specific agent, dose, and frequency (weekly vs daily).

How long you've been on the GLP-1 and at the current dose. Most GLP-1 nausea is worst in the first 1-2 months and during dose escalations; we like to know where you are in that trajectory.

Whether you've experienced significant nausea, vomiting, or appetite changes recently. Persistent severe nausea or vomiting on a GLP-1 isn't a ketamine contraindication, but it may warrant a conversation with your prescribing physician about whether the dose is right.

Your injection schedule, so we can plan ketamine session days that don't fall on or shortly after injection day when possible.

Whether you've had any new mood changes since starting the GLP-1 (per the section above).

For most patients, the conversation is brief and ketamine onboarding proceeds normally with the session-day protocol layered in.

Bottom line

Ozempic, Wegovy, Mounjaro, Zepbound, and other GLP-1 receptor agonists combine safely with at-home ketamine therapy. There is no documented pharmacologic interaction between the two drug classes, and continuing your GLP-1 throughout your ketamine course is the standard approach. The adjustments we make are session-day operational: extend your pre-session fast to 4-6 hours, pre-medicate with ondansetron if you've had GLP-1 nausea, hydrate aggressively the day before, and separate injection day from session day when scheduling allows. These four small changes prevent the avoidable problem (compounded session-day nausea) at near-zero cost to anything else, and the underlying GLP-1 treatment continues uninterrupted.